In-depth briefings on agency actions, clinical and preclinical research, and state and federal law and policy — with primary sources, scores, and clear limits on claims.
Study shows electrical stimulation mimics ketamine effects in neurons, suggesting potential non-drug therapies for depression.
Aug 01, 2026
Clinical TrialsA systematic review finds neuroimaging can predict ketamine treatment response, aiding personalized psychedelic therapies.
Jul 15, 2026
Clinical TrialsA French study is testing psilocybin from Red Light Holland, blending research and industry to explore brain effects.
Jun 08, 2026
Clinical TrialsA pilot trial of standardized psychedelic therapy shows promise for treating clinical depression, potentially influencing future treatment protocols.
Jun 08, 2026
NeuroscienceA new hypothesis suggests psilocybin may influence ADHD by altering neuroplasticity, but further research is needed.
Jun 05, 2026
Public HealthA cross-national study shows increasing nonmedical use of psychedelics, stressing the need for more clinical trials and clearer therapeutic guidelines.
Jun 05, 2026
Clinical TrialsA systematic review shows ketamine and esketamine offer rapid relief for treatment-resistant depression, but require careful use and monitoring.
Jun 05, 2026
Clinical TrialsClearmind Medicine's CMND-100 trial insights could influence future clinical strategies and market dynamics in psychedelic research.
Jun 05, 2026
PolicyThe EPA's TSCA submissions may influence the regulatory landscape for psychedelic compounds, affecting research and market dynamics.
Jun 05, 2026
Clinical TrialsA new study develops a coding system to observe awe in psilocybin therapy, potentially improving therapeutic outcomes and informing future research.
Jun 05, 2026
Clinical TrialsArizona's psilocybin trial marks a pivotal moment in psychedelic research, potentially shaping future clinical practices and regulatory policies.
Jun 05, 2026
PolicyThe EPA's proposed SNURs under TSCA may impact the manufacturing and processing of chemicals used in psychedelic research, requiring a 90-day notification for significant new uses.
Jun 05, 2026
Clinical TrialsA study examines how therapeutic alliances may reduce negative effects of ego dissolution in psilocybin therapy for depression.
Jun 04, 2026
Clinical TrialsCase reports, though low on the evidence hierarchy, play a crucial role in advancing psychedelic research by identifying rare reactions and catalyzing new treatments.
Jun 04, 2026
Clinical TrialsCase reports, though often overlooked, play a crucial role in medical advancements and treatment approvals, such as esketamine for depression.
Jun 04, 2026
Clinical TrialsThis analysis explores ketamine's role in couple therapy, highlighting potential benefits and the need for standardized protocols.
Jun 04, 2026
EthicsEuthanasia and assisted suicide in psychiatric contexts face legal and ethical complexities, requiring standardized criteria and multidisciplinary evaluations.
Jun 04, 2026
NeuroscienceA kainic acid-induced pig model of epilepsy offers a translational bridge for neuromodulation therapies, advancing research in device development.
Jun 04, 2026
Clinical TrialsA critical review evaluates classic psychedelics for chronic pain, emphasizing neuroplasticity, psychological effects, and the need for more research.
Jun 04, 2026
Clinical TrialsMDMA-Assisted Therapy (MDMA-AT) shows promise in reducing social anxiety disorder symptoms, with no serious adverse events, supporting further research.
Jun 04, 2026
NeuroscienceEEG study suggests VR-based awe exposure may aid emotional processing in affective disorders, highlighting potential therapeutic applications.
Jun 04, 2026
NeuroscienceResearch highlights ketamine's neurotoxic effects in adult female rats, raising questions about its safety in treating depression.
Jun 04, 2026
EthicsAI chatbots can reinforce delusions in substance-induced psychosis, complicating treatment. Clinicians must assess AI use and mitigate risks.
Jun 04, 2026
Clinical TrialsA study shows MDMA booster doses prolong effects without increasing peak intensity, crucial for optimizing PTSD therapy trials.
Jun 04, 2026
PolicyConnecticut expands its psychedelics pilot program, preparing for FDA approval and setting a state-level precedent for regulated psychedelic use.
Jun 04, 2026
Clinical TrialsA Las Vegas clinic highlights the growing acceptance of ketamine therapy for mental health, offering insights into its potential benefits and challenges.
Jun 04, 2026
Clinical TrialsA Los Angeles doctor introduces a ketamine-oxytocin nasal spray for mental health, raising questions about efficacy, regulation, and future research.
Jun 04, 2026
NeuroscienceRecent research finds no significant neural differences in cannabis cue tasks across CUD-risk groups, urging better diagnostic tools.
Jun 03, 2026
Clinical TrialsA feasibility trial indicates ketogenic therapy may reduce anorexia nervosa symptoms, warranting further research into its potential as a treatment.
Jun 03, 2026
NeuroscienceStudy reveals BNST activity's role in alcohol-seeking behavior during abstinence, highlighting potential targets for AUD treatment.
Jun 03, 2026
Clinical TrialsIbogaine shows promise for addiction treatment, but cardiac risks and regulatory gaps highlight the need for further research.
Jun 03, 2026
NeuroscienceA study links the N100 potential to fronto-limbic metabolism in MDD, suggesting a compensatory mechanism that could guide targeted therapies.
Jun 03, 2026
NeuroscienceHNK promotes antidepressant effects by enhancing astrocytic μ-δ opioid receptor heterodimerization, suggesting new therapeutic pathways.
Jun 03, 2026
NeuroscienceA study reveals shared molecular signatures in mood disorders, emphasizing the importance of sex-informed approaches in psychiatric research.
Jun 03, 2026
Clinical TrialsA study shows integrated treatment models may improve outcomes for patients with opioid use disorder and schizophrenia, reducing hospital visits.
Jun 03, 2026
Clinical TrialsA case series suggests iboga microdosing may aid recovery in traumatic brain injuries, though further research is needed.
Jun 03, 2026
PolicyThe FDA's faster pace in psychedelic research highlights the need for Washington to enact supportive policies for clinical integration.
Jun 03, 2026
Clinical TrialsA VA clinical trial on psychedelic therapy for veterans may influence Missouri policy, highlighting potential therapeutic benefits and safety.
Jun 03, 2026
NeuroscienceThe gut-brain axis may influence anxiety and depression, with dietary and probiotic interventions showing promise in early studies.
Jun 02, 2026
Clinical TrialsA recent study reveals placebo effects can mimic psychedelics, highlighting the need for rigorous trial designs and consideration of context.
Jun 02, 2026
Clinical TrialsThe European task force's consensus on TRLLD standardizes diagnostic criteria, enhancing research and treatment development for late-life depression.
Jun 02, 2026
Clinical TrialsA non-randomized trial suggests combining esketamine with psychotherapy may improve outcomes for treatment-resistant depression.
Jun 02, 2026
Clinical TrialsA preprint study explores at-home ketamine therapy for grief, offering insights but urging caution due to lack of peer review.
Jun 02, 2026
NeurosciencePlant metabolites may modulate neurotransmission in SUDs, but bioavailability and validation challenges remain.
Jun 02, 2026
Clinical TrialsThis analysis evaluates psychedelic-assisted therapies in palliative care, highlighting potential benefits and the need for rigorous trials.
Jun 02, 2026
Clinical TrialsThe integration of nonpharmacological methods with ketamine therapy may enhance neuroplasticity and improve behavioral therapy outcomes.
Jun 02, 2026
Clinical TrialsThe FDA is assessing how open-label designs in psychedelic trials affect efficacy and safety evaluations, potentially altering future guidelines.
Jun 02, 2026
NeuroscienceA preclinical study investigates ketamine's impact on chemobrain and depression in rats, revealing potential pathways for future cancer patient treatments.
Jun 01, 2026
Clinical TrialsA study reveals that esketamine can reduce postoperative anxiety in adolescents, though further research is needed to confirm these findings.
Jun 01, 2026
NeuroscienceBDNF's role as a biomarker in depression could revolutionize personalized treatment approaches, enhancing therapeutic outcomes.
Jun 01, 2026
Clinical TrialsA systematic review assesses ketamine's efficacy and safety in hip arthroplasty, with potential implications for clinical guidelines and pain management research.
Jun 01, 2026
Clinical TrialsIbogaine research shows potential in treating substance use disorders, but significant safety concerns and lack of robust trials remain.
Jun 01, 2026
Clinical TrialsContinuous subcutaneous ketamine infusion may affect the clearance of tacrolimus and sirolimus, highlighting the need for further research on drug interactions.
Jun 01, 2026
NeuroscienceMelsmon, a human placental extract, shows potential in reducing neuroinflammation in a preclinical depression model, warranting further human trials.
Jun 01, 2026
NeuroscienceRecent advancements in GPCR signaling understanding and multiplexed assays could revolutionize drug discovery for neurological disorders.
Jun 01, 2026
NeuroscienceStudy finds EEG markers in beta-band connectivity predict changes in depression and anxiety symptoms, offering potential for future interventions.
Jun 01, 2026
Clinical TrialsKetamine therapy shows promise for PTSD in veterans, but concerns about misuse and limited research highlight the need for cautious optimism.
Jun 01, 2026
NeuroscienceA recent study on DMT reveals neural and experiential dynamics, crucial for developing therapeutic protocols and influencing public health policies.
Jun 01, 2026
Clinical TrialsKetamine shows promise in surgical pain management, providing immediate analgesia and reducing opioid use, with implications for public health.
Jun 01, 2026
Clinical TrialsRecent research highlights how ketamine and psilocybin induce neuroplastic changes, offering new avenues for treating depression.
Jun 01, 2026
Clinical TrialsResearch on ketamine's stability with oncology drugs in children offers insights for safe administration in pediatric cancer settings.
Jun 01, 2026
NeuroscienceA systematic review of electrophysiological effects of psychedelics offers insights for clinical trials and biomarker development.
Jun 01, 2026
Clinical TrialsA systematic review highlights how classic psychedelics affect personality traits, emphasizing increased Openness and decreased Neuroticism.
May 31, 2026
Clinical TrialsA scoping review assesses Brazil's unique position in psychedelic research, highlighting Ayahuasca's rapid antidepressant effects and Ibogaine's potential for substance use disorders.
May 30, 2026
Clinical TrialsA new trial investigates MDMA-assisted psychotherapy for social anxiety in autistic adults, aiming to fill treatment gaps and inform future therapeutic protocols.
May 30, 2026
Clinical TrialsThis review examines oral ketamine's safety for depression and pediatric sedation, emphasizing short-term tolerability but uncertain long-term effects.
May 30, 2026
Clinical TrialsA systematic review of oral ketamine's safety highlights its potential and risks, influencing clinical trials and policy decisions.
May 30, 2026
Clinical TrialsAn analysis of US psychedelic facilitation training programs reveals insights into their quality and scope, impacting future policy and clinical practices.
May 29, 2026
Clinical TrialsA case study highlights ketamine's promise in treating pediatric status epilepticus when standard treatments fail, urging further trials.
May 29, 2026
Clinical TrialsA 2026 study examines psilocybin's potential to improve sleep and alter brain microstructure in chronic cluster headache patients.
May 29, 2026
Clinical TrialsThis review examines the pharmacokinetics of intramuscular ketamine, emphasizing its dose-dependent effects and the need for further research.
May 29, 2026
NeuroscienceThis study highlights how stress-induced epigenetic changes influence neurodegeneration in African diabetes patients, suggesting tailored interventions.
May 29, 2026
Clinical TrialsA systematic review highlights the potential of psychedelics to induce hypomania and mania, impacting clinical trials and policy guidelines.
May 29, 2026
Clinical TrialsA review highlights neuroplasticity as a promising avenue for treatment-resistant depression, emphasizing psychedelics and other plasticity-based interventions.
May 29, 2026
Clinical TrialsPsilocybin-assisted psychotherapy shows promise in reducing anxiety symptoms, but high study variability demands further rigorous trials.
May 29, 2026
NeuroscienceA study explores how NMDA antagonists affect negative biases in rats, providing clues for treating major depressive disorder.
May 29, 2026
Clinical TrialsA systematic review reveals ketamine's potential for rapid depression relief in cancer patients, highlighting the need for further research on long-term safety and dosing.
May 29, 2026
PolicyThe EPA's new SNURs under TSCA could delay psychedelic research by imposing notification requirements for certain chemical substances.
May 29, 2026
Clinical TrialsThe evolving landscape of clinical psychology emphasizes integrative treatment frameworks, influencing how psychedelic therapies may be incorporated into mental health care.
May 29, 2026
PolicyOMB's proposed revisions for federal financial assistance could impact psychedelic research funding, emphasizing transparency and accountability.
May 29, 2026
NeuroscienceProtocatechuic acid shows promise in neuroprotection across disorders like Alzheimer's, offering translational potential for clinical use.
May 29, 2026
Clinical TrialsKetamine's use in addiction treatment raises ethical and safety questions, highlighting the need for careful clinical protocols.
May 29, 2026
Clinical TrialsA systematic review suggests ketamine as a rapid-acting antidepressant for cancer patients, with potential benefits and calls for further research on long-term safety.
May 29, 2026
Clinical TrialsA systematic review details the pharmacokinetics of LSD, psilocybin, DMT, mescaline, and 5-MEO-DMT, aiding in optimizing dosing and safety.
May 29, 2026
Clinical TrialsA systematic review highlights ketamine's rapid antidepressant effects in cancer patients, emphasizing the need for further research on long-term safety and dosing.
May 29, 2026
Clinical TrialsA recent meta-analysis underscores the need for cautious patient selection in psychedelic-assisted therapies due to potential mania risks.
May 29, 2026
PolicyColorado's HB 26-1325 adds ibogaine to the Natural Medicine Health Act, impacting psychedelic research and regulation.
May 29, 2026
Clinical TrialsThe VA's MDMA therapy trial for PTSD and alcohol use disorder marks a pivotal moment in psychedelic research, possibly expanding treatment options.
May 29, 2026
Clinical TrialsA review of intramuscular ketamine pharmacokinetics offers insights into its absorption and metabolism, potentially refining clinical dosing strategies.
May 29, 2026
Clinical TrialsA systematic review highlights the pharmacokinetics of serotonergic psychedelics, aiding in optimizing dosing and safety for therapeutic use.
May 29, 2026
Clinical TrialsThe VA's MDMA trial and psilocybin's enduring effects highlight advancements in psychedelic therapy for mental health.
May 29, 2026
Public HealthResearch highlights the neurological risks of nitrous oxide abuse, linking it to vitamin B12 deficiency and urging timely clinical intervention.
May 28, 2026
NeuroscienceResearch on Guipi pill reveals antidepressant effects via the gut-brain axis, highlighting immune modulation as a key mechanism.
May 28, 2026
Clinical TrialsNew research highlights ketamine's impact on epigenetic aging, suggesting potential therapeutic applications in longevity and mental health.
May 28, 2026
Clinical TrialsA study assesses blinding integrity in psychedelic trials, highlighting challenges with psilocybin, MDMA, and methylphenidate.
May 28, 2026
NeuroscienceA new friction-theoretic framework may reshape approaches to treatment-resistant depression, impacting psychedelic research.
May 28, 2026
NeuroscienceA novel friction-theoretic framework offers insights into complex diseases, including treatment-resistant depression, potentially informing psychedelic-assisted therapies.
May 28, 2026
Clinical TrialsA new research program introduces trial-design templates for compound race pathology, enhancing psychedelic therapies' precision and efficacy.
May 28, 2026
Clinical TrialsThis paper introduces five trial-design templates for psychedelic interventions, offering structured methodologies to enhance clinical trial precision.
May 28, 2026
Clinical TrialsKetamine shows promise for depression treatment, but safety and addiction risks remain key research areas.
May 28, 2026
Clinical TrialsA case of syncope during a psilocybin trial underscores the importance of cardiovascular monitoring and systematic documentation of adverse events.
May 28, 2026
Clinical TrialsA case study suggests psilocybin may temporarily unlock functional capacities in advanced Alzheimer's, warranting further research.
May 28, 2026
Clinical TrialsThe 5-HT2B receptor offers promise for treatment-resistant depression but poses cardiac risks, necessitating cautious development of therapies.
May 28, 2026
Clinical TrialsA trial shows esketamine-based anesthesia improves recovery in elderly lung surgery patients, suggesting potential shifts in anesthesia practices.
May 28, 2026
Clinical TrialsThis meta-analysis examines dose-dependent adverse events of esketamine in treatment-resistant depression, emphasizing precision dosing.
May 28, 2026
Clinical TrialsA case of psilocybin-induced syncope underscores the need for robust safety protocols in psychedelic-assisted therapy.
May 28, 2026
Clinical TrialsVA's MDMA-assisted therapy trial could transform PTSD treatment, signaling potential policy shifts and increased research funding.
May 28, 2026
PolicyCalifornia advocates are preparing a 2026 ballot initiative to legalize psilocybin and MDMA. The push follows years of legislative setbacks — Governor Newsom vetoed SB 58 in 2023, and Sen. Scott Wiener's SB 1012 stalled in Appropriations. SB 751, a narrower veterans-and-first-responders research pilot, is moving in parallel.
May 28, 2026
NeuroscienceA systematic review reveals ketamine's dual neurotoxic and neuroprotective effects, offering insights for clinical and policy guidelines.
May 27, 2026
NeuroscienceA study reveals specific molecular and network features underlying cortical atrophy in dementia with Lewy bodies, highlighting mitochondrial and synaptic genes.
May 27, 2026
Clinical TrialsA systematic review highlights ketamine's complex neurotoxic and neuroprotective effects, influencing future clinical guidelines and research.
May 27, 2026
NeuroscienceResearch on 4-MeO-MiPT reveals its dual action as a 5-HT2A agonist and SERT inhibitor, suggesting potential for tailored therapeutic psychedelics.
May 27, 2026
NeuroscienceNew research highlights how psychedelics activate GPCRs, providing insights into their antidepressant effects and potential for targeted therapies.
May 27, 2026
Clinical TrialsA Phase 2b trial reveals psilocybin's sustained antidepressant effects in treatment-resistant depression, informing future research and policy.
May 27, 2026
Clinical TrialsA phase 2b trial shows psilocybin's long-term efficacy in treatment-resistant depression, supporting its potential integration into clinical guidelines.
May 27, 2026
Clinical TrialsA phase 2b trial reveals psilocybin's long-term efficacy in treatment-resistant depression, influencing future clinical guidelines.
May 27, 2026
Clinical TrialsA clinical trial reveals psilocybin's potential to quickly alleviate depression symptoms, influencing future research and policy.
May 27, 2026
Clinical TrialsThe evolution of ketamine-assisted psychotherapy highlights changes in treatment protocols, impacting clinical practices and market dynamics.
May 27, 2026
Clinical TrialsThis analysis discusses ketamine's trial limitations for depression, personalized antipsychotic use, and cognitive interventions, highlighting clinical implications.
May 26, 2026
NeuroscienceA recent study proposes using childhood development as a model to understand psychedelic effects, highlighting neural plasticity parallels.
May 26, 2026
Clinical TrialsThe VA's MDMA trial for PTSD could transform treatment protocols, offering new hope for veterans and influencing future policy decisions.
May 26, 2026
NeuroscienceA systematic review examines fractal analysis in neuroimaging, highlighting its promise in psychiatric diagnosis but noting the need for standardized protocols.
May 26, 2026
Public HealthAustralia considers specialist clinics to improve access to novel treatments for treatment-resistant depression, addressing economic and regulatory barriers.
May 26, 2026
Clinical TrialsA recent study reveals a lack of clinical preparedness for addressing long-term psychological complications from psychedelic use, urging better training and destigmatization.
May 26, 2026
NeuroscienceMarinobufagin, a compound with antitumor properties, shows neurotoxic effects by inducing seizures, offering insights for anticonvulsive research.
May 26, 2026
Clinical TrialsThe VA's MDMA-assisted therapy trial could redefine PTSD treatment for veterans, influencing future policy, research, and market dynamics.
May 26, 2026
PolicyThe FDA's renewal of its Drug Safety Advisory Committee ensures ongoing oversight, impacting psychedelic drug safety assessments.
May 26, 2026
PolicyThe DEA proposes diphenidine as a Schedule I substance, impacting research and market potential while aligning with international obligations.
May 26, 2026
NeuroscienceStudy reveals how vagal nerve stimulation suppresses seizures by enhancing vagal activity, informing future epilepsy treatments.
May 25, 2026
NeuroscienceA study on planarians reveals psilocybin's impact on serotonin pathways, offering insights for human clinical trials.
May 25, 2026
PolicyUkraine considers psychedelic therapy for PTSD, requiring legislative changes and clinical trials to establish a regulated model.
May 25, 2026
PolicyUkraine explores psychedelic therapy for PTSD in veterans, facing legal hurdles. Potential parallels with Australia and Switzerland's models.
May 25, 2026
Clinical TrialsA scoping review on postpartum depression reveals its complexity, highlighting prevalence, risk factors, and emerging therapies like neurosteroids.
May 25, 2026
NeurosciencePsilocybin modulates social behavior in mice over time, offering insights for future research on its therapeutic potential.
May 25, 2026
Clinical TrialsA Swedish study reveals psilocybin's potential for rapid depression relief, offering an alternative to traditional antidepressants.
May 25, 2026
NeuroscienceA study on psilocybin shows sex-specific effects on social behavior in mice, emphasizing the need for sex-informed psychedelic research.
May 25, 2026
NeuroscienceNew research suggests targeting the spleen-gut-brain axis could offer innovative treatments for depression, focusing on immune and microbiota modulation.
May 24, 2026
NeuroscienceA study on rats explores anxiety modulation by flumazenil, midazolam, and ketamine, with implications for human anxiety treatment research.
May 24, 2026
Clinical TrialsThis analysis examines the therapeutic potential of psychedelics, their mechanisms, trial progress, and regulatory challenges.
May 24, 2026
Clinical TrialsNew research highlights the potential of psychedelics in treating mental health disorders, influencing future clinical trials and policy decisions.
May 24, 2026
Clinical TrialsStudy examines speech changes post-5-MeO-DMT retreat, offering insights into non-invasive measures of psychedelic therapy outcomes.
May 23, 2026
Clinical TrialsResearch shows ketamine's dose-dependent effects on postoperative hallucinations, stressing the need for precise dosing in surgical settings.
May 23, 2026
Clinical TrialsA systematic review highlights ketamine's potential in ICU sedation, affecting ventilation duration, ICU stay, and delirium, with implications for clinical guidelines.
May 23, 2026
Clinical TrialsKetamine shows promise in treating drug-resistant bipolar depression, emphasizing polypharmacotherapy and personalized medicine.
May 23, 2026
EthicsThe discernibility challenge in moral neuroenhancement raises ethical questions about distinguishing between direct and indirect interventions.
May 23, 2026
Public HealthMind Medicine Australia seeks a grant for MDMA therapy for PTSD, aiming to enhance access and integrate treatments into Australia's healthcare.
May 23, 2026
Clinical TrialsA study explores ibogaine's potential in opioid recovery through lived experiences, highlighting the need for further clinical trials to assess efficacy and safety.
May 22, 2026
Clinical TrialsA recent study highlights ketamine's ability to alter brain connectivity, offering potential for rapid treatment in severe depression cases.
May 22, 2026
Clinical TrialsThis analysis explores the impact of ketamine and esketamine on suicidal ideation and emergency department visits in treatment-resistant depression.
May 22, 2026
Clinical TrialsThis study from Benue State, Nigeria, highlights the impact of therapeutic alliances on depression treatment, offering insights for future psychedelic therapy protocols.
May 22, 2026
Clinical TrialsPsilocybin shows promise for treatment-resistant depression, but regulatory, ethical, and implementation hurdles remain.
May 22, 2026
Clinical TrialsPsilocybin-assisted therapy shows promise in reducing anxiety and depression in cancer patients, highlighting its potential in psychosocial oncology.
May 22, 2026
Clinical TrialsSubanesthetic ketamine may improve brain connectivity in treatment-resistant depression, offering new therapeutic pathways.
May 22, 2026
Clinical TrialsA systematic review suggests IL-10 as a biomarker and therapeutic target for treatment-resistant depression, focusing on neuroinflammation.
May 22, 2026
PolicyEPA's new SNURs under TSCA require 90-day notifications for certain chemicals, affecting psychedelic research supply chains.
May 22, 2026
PolicyA legal push for expedited psilocybin rescheduling by the DEA could reshape research access and market dynamics.
May 22, 2026
PolicyThe DEA's temporary Schedule I placement of 2-FDCK limits research and commercial use, citing public safety concerns.
May 22, 2026
NeuroscienceL-FAME dataset enhances understanding of meditation's impact on brain activity, aiding future research and clinical applications.
May 21, 2026
NeurosciencePsiConnect study uses neuroimaging to explore psilocybin's brain effects, informing clinical trials and potential therapies.
May 21, 2026
Clinical TrialsA study investigates ketamine and D-Cycloserine/lurasidone therapy for bipolar depression, potentially impacting treatment protocols.
May 21, 2026
Clinical TrialsA taxonomy of non-prescription pre-session support practices in psychedelic contexts aims to standardize and improve safety.
May 21, 2026
Clinical TrialsRecent developments in Parkinson's Disease treatments focus on novel drug delivery and new agents, yet disease-modifying therapies remain elusive.
May 21, 2026
Clinical TrialsA systematic review of VR interventions shows potential in treating obesity and eating disorders, with promising clinical outcomes but limited by small sample sizes.
May 21, 2026
NeuroscienceA groundbreaking fMRI study unveils mescaline's unique impact on cerebellar function and brain connectivity, informing future research on its therapeutic potential.
May 21, 2026
NeuroscienceA study highlights the correlation between traditional ceremony durations and pharmacokinetic effects, suggesting potential validity in indigenous practices.
May 21, 2026
NeurosciencePsiConnect uses multimodal imaging to study psilocybin's context-dependent effects, offering insights into neural and subjective impacts.
May 21, 2026
Clinical TrialsA dual-modal diagnostic model using metabolomics and clinical data shows high accuracy in diagnosing treatment-resistant depression.
May 21, 2026
Clinical TrialsKetamine is being studied as a treatment for anxiety, marking a shift from its recreational use. This development could impact mental health treatment strategies.
May 21, 2026
Clinical TrialsA single psilocybin dose could reshape the brain, offering weeks of relief from mental health conditions, pending further research.
May 21, 2026
PolicyThe DEA is urged to reschedule psilocybin following an order from former President Trump, signaling a potential shift in federal psychedelic policy.
May 21, 2026
PolicyThe EPA extends the comment period for SNURs under TSCA, impacting regulatory timelines for chemical substances.
May 21, 2026
PolicyThe DEA's expanded subpoena authority may increase oversight in psychedelic research, impacting compliance and industry practices.
May 21, 2026
Clinical TrialsA Swiss survey on psychedelic-assisted therapy methods underscores the need for standardized protocols and training.
May 20, 2026
Clinical TrialsA study on cannabidiol for paediatric epilepsy shows mixed results: 40% improved, but high discontinuation rates suggest further research is needed.
May 20, 2026
NeuroscienceA paradigm shift in addiction research highlights multisystem interactions beyond dopaminergic pathways, identifying SVTg as a key node.
May 20, 2026
NeuroscienceResearch maps how chronic stress alters neural circuits in the prefrontal cortex, affecting depression-like behaviors and highlighting the need for targeted treatments.
May 20, 2026
NeuroscienceA recent study uses in silico methods to analyze ayahuasca's compounds, stressing the need for further in vivo research.
May 20, 2026
Clinical TrialsA study investigates ketamine's effects on hemodynamics in depression, highlighting potential therapeutic and safety considerations.
May 20, 2026
Clinical TrialsA trial combining D-Cycloserine with iTBS for fibromyalgia was terminated early, showing no significant benefit over placebo except for depressive symptoms.
May 20, 2026
NeuroscienceMicroglia's functional states in neuropsychiatric disorders are characterized, revealing potential therapeutic targets for mental health treatments.
May 20, 2026
Clinical TrialsStudy highlights psychiatric adverse events in ketamine use for depression, emphasizing the need for larger trials to assess safety.
May 20, 2026
NeuroscienceA novel framework using deep neural networks to understand altered states could revolutionize research and clinical applications.
May 20, 2026
Clinical TrialsMDMA-assisted therapy shows moderate efficacy in reducing trauma but suffers from poor harm reporting, necessitating more rigorous trials.
May 20, 2026
Clinical TrialsEsketamine, combined with dexmedetomidine, may lower postpartum depression incidence and improve sleep in high-risk parturients.
May 20, 2026
Clinical TrialsThe opening of a ketamine treatment facility for depression marks a significant step in psychedelic-assisted therapy, with implications for research and policy.
May 20, 2026
Clinical TrialsThe FDA's Breakthrough Therapy designation for a psilocybin analogue in treating postpartum depression highlights the potential of psychedelics in mental health.
May 20, 2026
PolicyThe DEA's updated list of exempt chemical preparations may significantly impact psychedelic research, affecting compliance and availability.
May 20, 2026
PolicyThe VA's proposed rule on PDMP access seeks to enhance prescription safety by clarifying definitions and mandating information sharing.
May 20, 2026
PolicyThe DEA's proposed revisions to quota regulations aim to balance supply and demand for schedule I and II substances, impacting psychedelic research.
May 20, 2026
Clinical TrialsA recent trial suggests low-dose buprenorphine post-ketamine may reduce suicidal ideation in MDD, offering new treatment insights.
May 19, 2026
CommunityA survey study highlights how Brazilians integrate psychedelics into daily life, offering insights for therapeutic frameworks and community support.
May 19, 2026
Clinical TrialsBuprenorphine and ketamine combination shows promise in reducing suicidal tendencies, but further research is needed to confirm efficacy and safety.
May 19, 2026
Clinical TrialsA systematic review evaluates antenatal exposure to classic psychedelics, revealing mixed outcomes for maternal and child health. Further research is needed.
May 19, 2026
Public HealthA study reveals the widespread use of contemplative practices like meditation and yoga in Australia and New Zealand, highlighting their potential role in mental health management.
May 19, 2026
NeuroscienceThis study advances BrainAge models as biomarkers for childhood brain health, using neuroimaging to aid early intervention strategies.
May 19, 2026
Clinical TrialsA Stanford study reveals a drug combination that extends ketamine's antisuicidal effects, potentially transforming treatment protocols for severe depression.
May 19, 2026
PolicyThe FDA's fast-track review of psychedelics may accelerate their availability for mental health treatment, reflecting growing federal acceptance.
May 19, 2026
Clinical TrialsRecent advances in ketamine-assisted psychotherapy highlight its potential in treating depression and PTSD, offering new avenues for research and clinical application.
May 19, 2026
Clinical TrialsThe Bethesda clinic's ketamine treatments for depression mark a shift in mental health care, emphasizing the need for further research on efficacy and safety.
May 19, 2026
Clinical TrialsKarolinska Institutet's study on psilocybin for depression may influence future treatments and regulatory decisions.
May 19, 2026
Evergreen guides, US and state policy orientation, and daily signal on science and regulation — The Psychedelic Journal as one journal voice.
Global psychedelic research, law, and access (pillar guide)
US and state law, scheduling, and policy hub (not legal advice)
Guides — plain-English primers on each psychedelic therapy
Tools — quizzes, provider lookups, legal-status checkers
Policy calendar: comment windows and milestones we track on-page
Data hub: calendars, tools, and structured research datasets
Glossary A–Z across compounds, law, and policy terms
Sources & method: what we ingest, how we score it, and limits
Curated reading paths for onboarding and deeper study
Start here: how to use this journal and where to go next
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.